Biogen Sues Amgen Over Infergen
Biogen has filed suit against Amgen claiming violations of three patentsin the manufacture of Amgen's Infergen (consensus interferon or interferon alphacon-1), which is under review by the US Food and Drug Administration for the treatment of hepatitis C virus infection.
If approved, Infergen would compete with Biogen's Intron A (interferon alfa-2b), which is the only approved drug to treat the infection in the USA. Intron A is licensed to and sold by Schering-Plough. S-P filed its own suit against Amgen alleging patent infringement last year (Marketletter December 9).
Biogen's suit alleges that Amgen's manufacturing processes for Infergen utilize technology developed by Biogen, and asks for compensation, triple damages and that Amgen be prevented from infringing the patent. Amgen said it had not yet received details of the suit but that Infergen has been in development at the company since the 1980s.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze